Analysts are on the Bearish side about Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) this week.

June 10, 2018 - By Robert Crowder

Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) Logo

Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) Ratings Coverage

Among 4 analysts covering Adamis Pharmaceuticals (NASDAQ:ADMP), 4 have Buy rating, 0 Sell and 0 Hold. Therefore 100% are positive. Adamis Pharmaceuticals had 4 analyst reports since March 23, 2018 according to SRatingsIntel. On Friday, March 23 the stock rating was maintained by B. Riley & Co with “Buy”. Maxim Group maintained Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) rating on Monday, May 14. Maxim Group has “Buy” rating and $10 target. The rating was maintained by FBR Capital with “Buy” on Monday, May 14. Below is a list of Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) latest ratings and price target changes.

14/05/2018 Broker: FBR Capital Rating: Buy New Target: $6.2500 Maintain
14/05/2018 Broker: Maxim Group Old Rating: Buy New Rating: Buy Old Target: $5 New Target: $10 Maintain
23/04/2018 Broker: H.C. Wainwright Rating: Buy New Target: $7 Initiates Coverage On
23/03/2018 Broker: B. Riley & Co Old Rating: Buy New Rating: Buy Old Target: $7.5 New Target: $6.25 Maintain

The stock increased 1.85% or $0.075 during the last trading session, reaching $4.125. About 250,913 shares traded. Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) has risen 14.47% since June 10, 2017 and is uptrending. It has outperformed by 1.90% the S&P500.

Adamis Pharmaceuticals Corporation, a specialty biopharmaceutical company, develops and commercializes products in the therapeutic areas of allergy and respiratory disease in the United States. The company has market cap of $137.73 million. The companyÂ’s specialty pharmaceutical product candidates comprise Epinephrine Injection pre-filled syringe for use in the emergency treatment of acute allergic reactions, including anaphylaxis; dry powder inhaler products consisting of albuterol (APC-2000) and fluticasone (APC-4000) for the treatment of bronchospasm and asthma; and beclomethasone (APC-1000), a metered dose inhaler product for the asthma, as well as APC-1000 and APC-5000 for the treatment of asthma and chronic obstructive pulmonary disease. It currently has negative earnings. It also operates a 503B drug outsourcing facility that provides prescription compounded medications to patients, physician clinics, hospitals, surgery centers, and other clients in the United States.

Another recent and important Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) news was published by Seekingalpha.com which published an article titled: “Adamis Pharmaceuticals: Paging Dr. Carlo” on May 14, 2018.

Adamis Pharmaceuticals Corporation (NASDAQ:ADMP) Ratings Chart

Receive News & Ratings Via Email - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings with our FREE daily email newsletter.




Free Email Newsletter

Enter your email address below to get the latest news and analysts' ratings for your stocks with our free daily email newsletter: